ReviewAmerican journal of stem cells2017
A review of the emerging potential therapy for neurological disorders: human embryonic stem cell therapy.
Review in American journal of stem cells, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- A Review of The Place of Adipose-Derived Stem Cells among Stem Cell Applications in Neurodegenerative Diseases.Current topics in medicinal chemistry · 2026Review
- Human stem cells loaded with visible and near-infrared fluorescent core-shell polymeric nanoparticles and revealing tropism toward inflammatory stimuli: in vitro evaluation.Stem cell research & therapy · 2025Article
- Transplantation of fibrin-thrombin encapsulated human induced neural stem cells promotes functional recovery of spinal cord injury rats through modulation of the microenvironment.Neural regeneration research · 2024Article
- Different macaque brain network remodeling after spinal cord injury and NT3 treatment.iScience · 2023Article
- Stem Cell Secretome for Spinal Cord Repair: Is It More than Just a Random Baseline Set of Factors?Cells · 2021Review
- Genetic modification by overexpression of target gene in mesenchymal stromal cell for treating liver diseases.Journal of molecular medicine (Berlin, Germany) · 2021Review
- Embryonic Stem Cells in Clinical Trials: Current Overview of Developments and Challenges.Advances in experimental medicine and biology · 2021Review
- Study of the Diffusion Tensor Imaging for Preclinical Therapeutic Efficacy of Umbilical Cord Mesenchymal Stem Cell Transplantation in the Treatment of Spinal Cord Injury.International journal of general medicine · 2021Article
- Regeneration of sciatic nerves by transplanted microvesicles of human neural stem cells derived from embryonic stem cells.Cell and tissue banking · 2020Article
- The Clinical Effect of Electroconvulsive Therapy and Its Relationship with Serum Levels of MMP-9 and CXCL12 in Patients with Mania.Neuropsychiatric disease and treatment · 2020Article
- Seeding hESCs to achieve optimal colony clonality.Scientific reports · 2019Article
- Crosstalk between stem cell and spinal cord injury: pathophysiology and treatment strategies.Stem cell research & therapy · 2019Review
- iPS-Cell Technology and the Problem of Genetic Instability-Can It Ever Be Safe for Clinical Use?Journal of clinical medicine · 2019Review
- Cholinergic Nerve Differentiation of Mesenchymal Stem Cells Derived from Long-Term Cryopreserved Human Dental Pulp In Vitro and Analysis of Their Motor Nerve Regeneration Potential In Vivo.International journal of molecular sciences · 2018Article
- Improvement of common variable immunodeficiency using embryonic stem cell therapy in a patient with lyme disease: a clinical case report.Clinical case reports · 2018Article
- Neurodevelopment at Age 10 Years of Children Born <28 Weeks With Fetal Growth Restriction.Pediatrics · 2017Observational
- Artificial Sperm: New Horizons in Procreation.Rambam Maimonides medical journal · 2017Review
- Stem Cell Therapy for Spinal Cord Injury.Cell transplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The first human embryonic stem cell (hESC) line was developed in the late nineties. hESCs are capable of proliferating indefinitely and differentiate into all the three embryonic germ layers. Further, the differentiation of hESC lines into neural precursor cells and neurons, astrocytes and oligodendrocytes showed their potential in treating several incurable neurological disorders such as spinal cord injury (SCI), cerebral palsy (CP), Parkinson's disease (PD). In this review, we will discuss the global scenario of research and therapeutic use of hESCs in the treatment of neurological disorders. Following this, we will discuss the development of a unique hESC line, how it differs from the other available hESC lines and its use in the treatment of neurological disorders. hESCs were isolated from mixture of neuronal and non-neuronal progenitor cells in their pre progenitor state in a Good Laboratory Practices, Good Tissue Practices and Good Manufacturing Practices compliant laboratory. Blastomere cells have served as a source to derive the hESCs and the xeno-free culture was demonstrated to be more safe and effective in clinical therapeutic application of hESCs. All the patients showed a remarkable improvement in their conditions and no serious adverse events were reported. This study concluded that hESC lines could be scalable and used in the treatment of various neurological disorders such as SCI, CP, and PD.
Indexed as
Identifiers
28533935PMC5435646What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.